Sterility and Mold (Fungal) Testing for Medical Devices: Standards, Methods, and Applications

Sterility and mold testing for medical devices is a critical microbiological verification activity that confirms products labeled as sterile are free from viable bacteria, yeasts, and molds, and that materials and manufacturing environments do not support fungal growth. This testing is mandated by standards such as ISO 11737-2, USP <71>, and GB/T 14233.2, and is typically performed by accredited third-party laboratories during sterilization validation, batch release, and regulatory submissions. This article explains the scope, sample types, test items, methodologies, and practical applications of sterility and mold examination for medical devices.

Technical Overview

Sterility and mold testing for medical devices encompasses two complementary microbiological examinations: the sterility test, which verifies the absence of all viable microorganisms on a product claimed to be sterile, and mold (fungal) testing, which detects, enumerates, or characterizes filamentous fungi and yeasts that may contaminate products, materials, or production environments. For devices labeled "sterile," a Sterility Assurance Level (SAL) of 10⁻⁶ is typically required, meaning the probability of a single viable organism on a device must not exceed one in one million.

Fungal contamination deserves specific attention in medical device manufacturing because molds such as Aspergillus, Penicillium, Fusarium, and Chaetomium thrive on natural polymers, cellulose-based packaging, plasticizers, and moisture-damaged facility surfaces. Invasive fungal infections associated with contaminated devices are especially dangerous for immunocompromised patients, and fungal growth can also degrade polymers, corrode electronics, and compromise package integrity. Regulatory frameworks addressing these risks include ISO 11737-2 (sterility testing for sterilization validation), ISO 11737-1 (bioburden), USP <71> and Ph. Eur. 2.6.1 (pharmacopoeial sterility tests), GB/T 14233.2 (biological test methods for infusion, transfusion, and injection equipment), and the Chinese Pharmacopoeia general chapters. Material resistance to fungi is evaluated under ASTM G21 and ISO 16869, while environmental fungal control follows ISO 14644 and ISO 14698.

Testing Samples

Sterile Single-Use Devices and Consumables

Disposable syringes, hypodermic needles, intravenous infusion sets, blood transfusion sets, urinary catheters, endotracheal tubes, and surgical instruments supplied sterile are subjected to sterility testing after terminal sterilization by ethylene oxide (ISO 11135), gamma or e-beam radiation (ISO 11137), or moist heat (ISO 17665). The complete product, including fluid pathways, is tested to detect any surviving microorganisms.

Implantable and Long-Term Contact Devices

Orthopedic implants, cardiac stents, pacemakers, hernia meshes, intraocular lenses, and sutures represent the highest risk category because they breach natural defense barriers or remain in contact with tissue for extended periods. Sterility and bioburden testing for these products is performed during sterilization process validation and routine release, often under aseptic processing controls aligned with GMP and ISO 13485 quality management requirements.

Wound Care, Dressings, and Textile-Based Products

Gauze, absorbent dressings, hydrocolloid and alginate wound care products, adhesive bandages, and cotton- or cellulose-based materials are intrinsically susceptible to fungal contamination due to their nutrient-rich, hygroscopic nature. These products require both sterility confirmation and, where applicable, direct fungal enumeration and identification of any mold isolates.

Drug-Device Combination and Preserved Products

Prefilled syringes, drug-eluting devices, metered-dose applicators, and multi-use devices containing preservatives require antimicrobial effectiveness (preservative efficacy) testing against fungal challenge organisms such as Candida albicans and Aspergillus brasiliensis, in addition to sterility verification of the sterile presentation.

Device Packaging, Raw Materials, and Components

Primary packaging such as Tyvek pouches, blister trays, and cellulose-based wraps, along with incoming polymer granules, latex, natural rubber, lubricants, and plasticized PVC components, may be evaluated for bioburden, fungal resistance, and the effectiveness of fungistatic compounds incorporated into plastics per ISO 16869.

Testing Items

The scope of testing is tailored to product type, sterilization method, and regulatory destination. Core test items include:

• Sterility test (membrane filtration or direct inoculation) per ISO 11737-2, USP <71>, Ph. Eur. 2.6.1, or GB/T 14233.2.
• Total bioburden determination, including enumeration of bacteria, yeasts, and molds, per ISO 11737-1.
• Mold and yeast count on non-sterile products or materials using selective fungal media such as Sabouraud dextrose agar.
• Identification of fungal isolates to genus or species level by microscopic morphology and molecular methods.
• Bacteriostasis and fungistasis (method suitability) validation to demonstrate the product does not inhibit microbial recovery.
• Antimicrobial (preservative) effectiveness testing against Candida albicans and Aspergillus brasiliensis per USP <51>.
• Fungal resistance of polymeric materials per ASTM G21 and ISO 16869.
• Environmental mold monitoring of cleanrooms and controlled environments per ISO 14644 and ISO 14698.

Testing Methods

Membrane Filtration Sterility Test

The preferred method for devices with extractable fluid pathways, filterable rinses, or soluble materials. The test article is rinsed with sterile diluent, the rinse fluid is passed through a 0.45 µm membrane filter that retains microorganisms, and the membrane is transferred into two media: Fluid Thioglycollate Medium (FTM) incubated at 30–35 °C for aerobic and anaerobic bacteria, and Soybean-Casein Digest Medium (TSB/SCDM) incubated at 20–25 °C, which supports fungal and aerobic bacterial growth. Per ISO 11737-2 and current USP <71> requirements, incubation is maintained for not fewer than 14 days, with daily or regular observation for turbidity and colony growth.

Direct Inoculation (Direct Transfer) Method

For devices that cannot be filtered, the intact product or its dissected components are immersed directly into the two culture media in specified volumes. This method is common for bulky devices, dressings, sutures, and tubings, with the same dual-medium, dual-temperature, 14-day incubation scheme. Any observed growth is confirmed by Gram stain and subculture, then identified.

Mold and Yeast Enumeration and Identification

For bioburden and material testing, samples are extracted in a validated recovery medium, and serial dilutions are plated onto Sabouraud dextrose agar (SDA), potato dextrose agar (PDA), or selective media such as Rose Bengal chloramphenicol agar and DG18 agar for xerophilic molds. Plates are incubated at 20–25 °C (or 25–28 °C depending on the method) for 5 to 7 days and up to 14 days for slow-growing fungi. Resulting colonies are counted, and representative isolates are identified by macroscopic and microscopic morphology and, where required, DNA sequencing for definitive species-level characterization.

Method Suitability (Bacteriostasis/Fungistasis) Validation

Before routine sterility testing, the laboratory must demonstrate that the product does not possess antimicrobial or antifungal properties that would mask contamination. Each medium is inoculated with a low level (typically ≤100 CFU) of standard strains, including Candida albicans ATCC 10231 in TSB and Clostridium sporogenes in FTM, and growth must be visually comparable to uninoculated controls. Recovery corrections and validation of removal of inhibitory substances are also applied to bioburden testing per ISO 11737-1.

Fungal Resistance Testing of Materials

Per ASTM G21, coupons of polymer, plastic, or coated materials are inoculated with a mixed spore suspension of Aspergillus brasiliensis, Penicillium funiculosum, Chaetomium globosum, Trichoderma virens, and Aureobasidium pullulans, then incubated at 28 ± 2 °C with relative humidity above 85% for 28 days. Growth is rated on a 0–4 visual scale, and any growth indicates the material can support fungal proliferation. Environmental and climatic mold testing of electrically powered or electronic medical equipment may also be performed per IEC 60068-2-10 and its national equivalents such as GB/T 2423.16 and JIS Z 2911.

Environmental Mold Monitoring

Cleanrooms and controlled production areas supporting sterile device manufacture are monitored using settle (passive) plates, active volumetric air samplers, surface contact plates, and swabs, cultured on fungal media at 20–25 °C. Trend analysis of mold counts, combined with identification of recurring isolates, supports biocontamination control programs under ISO 14698-1 and ISO 14698-2 and informs corrective actions such as HVAC remediation or material substitution.

Applications

Sterility and mold testing data serve multiple quality and regulatory purposes across the medical device lifecycle:

• Terminal sterilization validation, including initial and dose-auditing studies under ISO 11135, ISO 11137, and ISO 17665, where sterility testing of inoculated product confirms lethality.
• Routine batch release testing of sterile devices prior to distribution.
• Verification of aseptic filling and assembly processes for devices that cannot be terminally sterilized.
• Cleanroom qualification, routine environmental monitoring, and investigation of mold excursions in GMP-regulated facilities.
• Shelf-life and stability studies confirming that packaging and preservative systems prevent microbial and fungal proliferation over the claimed expiry period.
• Investigation of out-of-specification results, customer complaints, sterility failures, and product recalls, including root-cause identification of fungal contaminants.
• Technical documentation for regulatory submissions to authorities such as NMPA, FDA, and under the EU MDR, supported by test reports from accredited third-party laboratories operating to ISO/IEC 17025.

FAQ

What is the difference between a sterility test and a mold test?

A sterility test demonstrates the absence of all viable microorganisms, including bacteria, yeasts, and molds, on a product claimed sterile. A mold test specifically detects, enumerates, or identifies fungi on materials, non-sterile products, or in the manufacturing environment. The 20–25 °C soybean-casein digest medium used in the sterility test is capable of revealing fungal contamination, while dedicated mold tests use selective fungal media for greater sensitivity and characterization.

How long does sterility testing take?

The incubation period is not fewer than 14 days per ISO 11737-2, USP <71>, and Ph. Eur. 2.6.1. Including method suitability validation, sample preparation, and final observation, a routine sterility test typically requires approximately three to four weeks from sample receipt to reporting.

Which standards should a sterile device comply with?

Key references include ISO 11737-1 and ISO 11737-2 for bioburden and sterility testing, the applicable sterilization standard (ISO 11135, ISO 11137, or ISO 17665), USP <71> or Ph. Eur. 2.6.1 for pharmacopoeial sterility tests, GB/T 14233.2 for infusion and injection equipment in the Chinese market, and ISO 13485 for the underlying quality management system.

When is the membrane filtration method preferred over direct inoculation?

Membrane filtration is preferred whenever the product can be rinsed or dissolved, because larger sample quantities can be tested, inhibitory substances can be washed away, and the membrane provides a concentrated, uniform assay. Direct inoculation is reserved for solid, bulky, or insoluble devices that cannot be filtered.

Why is method suitability validation required?

Many devices contain antimicrobial residues, preservatives, or leachable chemicals that can suppress microbial growth in the culture media and generate false-negative sterility results. Method suitability (bacteriostasis/fungistasis) testing proves that low-level challenge organisms, including Candida albicans, grow reproducibly in the presence of the product, ensuring the test is genuinely capable of detecting contamination.

Can parametric release replace sterility testing?

For validated radiation or ethylene oxide sterilization processes with robust process controls and documented dose audits, parametric release may be approved by regulatory authorities in specific cases. However, sterility testing remains mandatory during initial sterilization validation and is still widely required for market release, particularly for aseptically processed products.